STAT+: Drugmakers, biotech VCs show ‘reinvigorated’ interest in osteoporosis treatments
Medicines for osteoporosis are grabbing the attention of the pharma industry, which has been incentivized by a long-awaited regulatory change.
The pharmaceutical industry has shown a renewed interest in developing treatments for osteoporosis, a condition that affects older adults and leads to brittle bones and fractures. This renewed focus has been spurred by a recent regulatory change that has incentivized drugmakers to revitalize their efforts in this area. Osteoporosis, which used to be a top priority for pharmaceutical companies like Eli Lilly, Merck, Novartis, and GSK, has seen its use stunted by cumbersome requirements and safety concerns associated with existing treatments.
Many eligible patients currently do not take advantage of these available therapies. However, several companies are now aiming to address this gap in the market. Eli Lilly, for instance, is actively recruiting scientists to work on osteoporosis therapies, according to Bloomberg. Other pharmaceutical firms are reportedly following a similar path.
In addition to traditional pharma companies, venture capitalists have also taken notice of the potential in bone health and have made it a priority area for investment.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
